P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Breast |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977623002424 |
| _version_ | 1797869935234383872 |
|---|---|
| author | S. Kümmel P. Schmid N. Harbeck M. Takahashi M. Untch J.-F. Boileau J. Cortes H. McArthur R. Dent J. O’Shaughnessy L. Pusztai T. Foukakis Y.H. Park R. Hui F. Cardoso C. Denkert Y. Zhu W. Pan V. Karantza P. Fasching |
| author_facet | S. Kümmel P. Schmid N. Harbeck M. Takahashi M. Untch J.-F. Boileau J. Cortes H. McArthur R. Dent J. O’Shaughnessy L. Pusztai T. Foukakis Y.H. Park R. Hui F. Cardoso C. Denkert Y. Zhu W. Pan V. Karantza P. Fasching |
| author_sort | S. Kümmel |
| collection | DOAJ |
| first_indexed | 2024-04-10T00:19:17Z |
| format | Article |
| id | doaj.art-df7da6e644f749229398d191714cb09f |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-04-10T00:19:17Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-df7da6e644f749229398d191714cb09f2023-03-16T05:02:17ZengElsevierBreast1532-30802023-03-0168S63S64P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 studyS. KümmelP. SchmidN. HarbeckM. TakahashiM. UntchJ.-F. BoileauJ. CortesH. McArthurR. DentJ. O’ShaughnessyL. PusztaiT. FoukakisY.H. ParkR. HuiF. CardosoC. DenkertY. ZhuW. PanV. KarantzaP. Faschinghttp://www.sciencedirect.com/science/article/pii/S0960977623002424 |
| spellingShingle | S. Kümmel P. Schmid N. Harbeck M. Takahashi M. Untch J.-F. Boileau J. Cortes H. McArthur R. Dent J. O’Shaughnessy L. Pusztai T. Foukakis Y.H. Park R. Hui F. Cardoso C. Denkert Y. Zhu W. Pan V. Karantza P. Fasching P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study Breast |
| title | P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study |
| title_full | P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study |
| title_fullStr | P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study |
| title_full_unstemmed | P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study |
| title_short | P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study |
| title_sort | p125 neoadjuvant pembrolizumab chemotherapy vs placebo chemotherapy followed by adjuvant pembrolizumab vs placebo for early tnbc surgical outcomes from the phase 3 keynote 522 study |
| url | http://www.sciencedirect.com/science/article/pii/S0960977623002424 |
| work_keys_str_mv | AT skummel p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT pschmid p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT nharbeck p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT mtakahashi p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT muntch p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT jfboileau p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT jcortes p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT hmcarthur p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT rdent p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT joshaughnessy p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT lpusztai p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT tfoukakis p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT yhpark p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT rhui p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT fcardoso p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT cdenkert p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT yzhu p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT wpan p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT vkarantza p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study AT pfasching p125neoadjuvantpembrolizumabchemotherapyvsplacebochemotherapyfollowedbyadjuvantpembrolizumabvsplaceboforearlytnbcsurgicaloutcomesfromthephase3keynote522study |